MK-7622

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

The MK-7622 is the first-of-its-kind oral positive allosteric modulator of M 1 muscarinic receptors, developed by Merck for the treatment of Alzheimer’s disease, with a structure comprising a benzoquinazolinone bearing additional complex substituents at positions 3 and 6. MK-7622 failed to pass Phase II clinical trials for the treatment of Alzheimer's disease (as an adjunctive therapy) and has been withdrawn from production.

The MK-7622 is the first-of-its-kind oral positive allosteric modulator of M 1 muscarinic receptors, developed by Merck for the treatment of Alzheimer’s disease, with a structure comprising a benzoquinazolinone bearing additional complex substituents at positions 3 and 6. MK-7622 failed to pass Phase II clinical trials for the treatment of Alzheimer's disease (as an adjunctive therapy) and has been withdrawn from production.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378804473 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.